AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02995915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
Study NCT02995915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
Study NCT02995915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment
Description: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
Study NCT02995915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment
Description: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
Study NCT02995915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
Study NCT02995915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Monitoring
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
Study NCT02251665 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: a single-center prospective observational study
Study NCT03354429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
Study NCT03354429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
Study NCT04206111 — intervention group
Intervention type: PROCEDURE
Intervention: Preoxygenation
Description: preoxygenation with high flow nasal cannula at 40l/min for 5min
Study NCT04465045 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy-hysteroscopy
Description: Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
Study NCT00981500 — intervention group
Intervention type: PROCEDURE
Intervention: gastric bypass
Description: Roux-en-Y gastric bypass
Study NCT00981500 — intervention group
Intervention type: PROCEDURE
Intervention: gastric banding
Description: laparoscopic adjustable gastric banding
Study NCT00981500 — intervention group
Intervention type: PROCEDURE
Intervention: sleeve gastrectomy
Description: vertical sleeve gastrectomy
Study NCT03862976 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: computerized cardiotocography
Description: computerized cardiotocography (C-CTG)
Study NCT03862976 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: computerized cardiotocography
Description: computerized cardiotocography (C-CTG)
Study NCT02285985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets: 5 mg
Study NCT02285985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets: 5mg
Study NCT05552040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START NOW Group
Description: START NOW psychotherapy is a CBT, DBT and skills-based intervention
Study NCT05552040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: START NOW Group
Description: START NOW psychotherapy is a CBT, DBT and skills-based intervention
Study NCT02440880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone in addition to TAP block in dose of 4 mg
Description: Dexamethasone in addition to TAP block in dose of 4 mg
Study NCT02440880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone in combination with TAP block in dose of 8 mg
Description: Dexamethasone in combination with TAP block in dose of 8 mg
Study NCT02440880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenous 4mg+ TAP block
Description: Dexamethasone intravenous in addition to TAP block in dose of 4 mg
Study NCT02440880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenous in addition to TAP block in dose of 8 mg
Description: Dexamethasone intravenous + TAP block in dose of 8 mg
Study NCT02440880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: TAP block without Dexamethasone neither intravenous nor in combination with the block
Study NCT02111486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: breakfast
Study NCT02111486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast
Study NCT00739336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention and Control
Description: The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
Study NCT00912405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steroid-Eluting Sinexus Intranasal Splint
Description: Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
Study NCT03746249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT03746249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study NCT04453384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAV-19
Description: Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
Study NCT04453384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
Study NCT03227380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: thoracic densitometry with contrast
Description: injected CT scan at 3 or 6 months after segmentectomy VATS
Study NCT02077517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux en Y Gastric Bypass
Study NCT02571894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subclinical cardiotoxicity surveillance and treatment
Description: Intervention arm receives cardiology assessment and intervention.
Study NCT04612491 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pre-operative Consultation
Description: Pre-operative consultation will be given before Mohs surgery
Study NCT01675713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Description: Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
Study NCT01537341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treadmill
Description: Participants will complete the intervention in 12-weeks, 3 times per week sessions.
Study NCT01537341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-belt
Description: Participants will complete the intervention in 12-weeks, 3 times per week sessions.
Study NCT01645475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin lyophilisate (Melt)
Description: Patient receives Desmopressin lyophilisate (Melt).
Study NCT03122912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
Study NCT03122912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Oil
Description: Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
Study NCT02111265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure
Study NCT02111265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: 1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure.
Study NCT02111265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
Study NCT02111265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index(BIS) monitor
Description: BiS is maintained at 40-60 during anesthesia.
Study NCT03642886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescribed Detraining
Description: Detraining is the deliberate act of reducing volume of exercise to observe subsequent changes in cardiac indices over time or the partial or complete loss of training of induced anatomical, physiological and performance adaptions. Detraining is primarily employed as a diagnostic tool to help differentiate Athletes' heart from cardiac pathology.
Study NCT03933709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Support System (NSS)
Description: Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
Study NCT03933709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deworming
Description: nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
Study NCT03933709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deworming
Description: nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
Study NCT03933709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: recommended diet
Description: WHO Diet
Study NCT02564172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMS group
Description: Conus medullaris stimulation with pentapolar surgical lead includes:~* Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~* Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~* If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~* If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect).
Study NCT02564172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMM group
Description: Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~* at effective dose, and minimal effective dose on the basis of adverse events and contraindications~* as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches...) will not be forbidden or contra-indicated.
Study NCT02493023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigated bronchoscopy
Study NCT02502084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3NT flexible endoscope
Description: The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
Study NCT02380716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® Ascending Stent Graft
Study NCT02194959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer PN
Description: Navigation by Peer Patient Navigators
Study NCT02194959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pro PN
Description: Navigation by Standard Hospital Navigators
Study NCT01018264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate (VESIcare)
Description: up to 10mg every day orally
Study NCT01018264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
Study NCT00626977 — intervention group
Intervention type: DRUG
Intervention: ropivacaine
Description: 15 ml of ropivacaine 0.125% peridural once
Study NCT00626977 — intervention group
Intervention type: DRUG
Intervention: ropivacaine and clonidine
Description: 15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
Study NCT03294369 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
Study NCT02772016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colla corii asini
Description: 15 g of Colla corii asini in powder form daily for 4 weeks
Study NCT04455893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stratified Transplant Survival
Description: The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
Study NCT04051840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic (Baxter Healthcare, Deerfield, IL, USA)
Description: ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
Study NCT01041807 — intervention group
Intervention type: DRUG
Intervention: amlodipine/losartan
Description: amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
Study NCT02359292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 HS 200/6/25 pMDI
Study NCT02359292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 MS 100/6/25 pMDI
Study NCT02359292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 HS 200/6/25 pMDI + Charcoal Block
Study NCT02359292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 MS 100/6/25 pMDI + Charcoal Block
Study NCT02359292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pMDI
Study NCT00000410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diskectomy
Description: The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
Study NCT00000410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
Study NCT01280929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation (PRP)
Study NCT01280929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation (PRP)
Study NCT01280929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous injection of ranibizumab
Study NCT03427372 — intervention group
Intervention type: BEHAVIORAL
Intervention: anxiety scale, depression scale
Description: post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
Study NCT02197546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Acupuncture & acupressure
Description: Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
Study NCT05846009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442501
Description: Subcutaneous injection
Study NCT05846009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT02752412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02752412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine U100 (HOE901)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02752412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02752412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01116089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bramitob® administered by PARI LC® PLUS nebulizer
Description: (tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
Study NCT01116089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bramitob® administered by PARI eFlow® rapid electronic nebulizer
Description: (tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
Study NCT03324165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proposed Algorithm
Description: Proposed algorithm that uses Alvarado Score to guide CT utilization
Study NCT05631080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Endoscpic enucleation of the Prostate
Description: Transurethral endoscopic enucleation of the prostate adenoma
Study NCT02841618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Linoleic Acid Healthy Cookies
Study NCT02841618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Oleic Acid Healthy Cookies
Study NCT04096560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.
Study NCT04096560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-994 placebo-matching tablets.